EGFL7 and hepatocellular carcinoma: Moreover, the sensitivity and accuracy of Egfl7 in distinguishing early HCC patients from the non-HCC individuals were also better than AFP in the Validation Cohort (75.9% vs. 58.9%, P < 0.0001; 76.0% vs. 73.3%, P = 0.024; Table 6).